Close

Not a member yet? Register now and get started.

lock and key

Sign in to your account.

Account Login

Forgot your password?

Healthcare  // Browsing posts in Healthcare

Novadaq Technologies Idea Proposal

Novadaq Technologies Idea Proposal

Research Question: Will Novadaq’s SPY Elite be widely adopted and drive the company’s growth in 2016? Report Available: Nov. 24, 2015   Blueshift’s initial research shows NVDQ’s sales momentum increasing now that its technology is transitioning into the adoption phase. But its SPY fluorescence imaging systems could still be years away from achieving angiography gold standard status, […]

Read more...

Blockbuster Sales Not in Store for Depomed’s Nucynta

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as the company takes on OxyContin among acute pain patients and Lyrica and Cymbalta in neuropathic pain patients? Companies: DEPO, HZNP, JNJ, LLY, PFE, TSE:ENL By: David Franklin Click here to download the report (.pdf)   Summary of Findings Depomed Inc.’s (DEPO) Nucynta and Nucynta […]

Read more...

Abiomed’s Impella Will Drive Growth But Not at Projected 40%

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Companies: ABMD, STJ By: David Franklin Click here to download the report (.pdf)   Summary of Findings The Impella Platform is expected to drive growth for Abiomed Inc. (ABMD) but not at corporate’s 2020 projected sales rate of $1.2 billion to $1.8 billion, […]

Read more...

Depomed Idea Proposal (DEPO)

Depomed Idea Proposal (DEPO)

Research Question: Will Depomed’s Nucynta and Nucynta ER achieve blockbuster status as it takes on OxyContin with acute pain patients and Lyrica/Cymbalta with neuropathic pain patients? Report Available: Oct. 29, 2015   Blueshift’s initial research shows DEPO sold $57 million worth of painkiller Nucynta in its first quarter and believes it has the potential to reach $1 […]

Read more...

Seres’ SER-109 Likely Will Be the First Microbiome Therapy to Market

Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to treat Clostridium difficile infections? Companies: ALIOF/VTX:ATLN, MCRB, MRK, NVS, PFE, SHPG, SNY, SYN By: David Franklin Click here to download the report (.pdf)   Summary of Findings Seres Therapeutics Inc.’s (MCRB) Phase 2 drug, SER-109, is expected to be the first […]

Read more...

Scotts Miracle-Gro Idea Proposal (SMG)

Scotts Miracle-Gro Idea Proposal (SMG)

Research Question: Will Scotts Miracle-Gro’s entry into the hydroponics/marijuana market spur the company into high-growth mode?   Report Available: Oct. 23, 2015   Blueshift’s initial research shows SMG expanding into the hydroponics market, a sector likely to experience double-digit growth for years to come. However, hydroponics’ user base, many of whom grow marijuana, shudder at […]

Read more...

Abiomed Idea Proposal

Abiomed Idea Proposal

Research Question: Will the Impella propel Abiomed to achieve its 40% growth projections? Report Available: October 14, 2015   Blueshift’s initial research shows ABMD’s Impella utilization rate is increasing faster than many had expected in its Q1. ABMD, a leader in heart support technologies, then issued an aggressive five-year strategy which predicted $1.2 billion to $1.8 billion in […]

Read more...

Seres Therapeutics Idea Proposal

Seres Therapeutics Idea Proposal

Research Question: Will Seres Therapeutics’ SER-109 be the first approved and best microbiome therapy to cure Clostridium difficile infection? Report Available: October 1, 2015   Blueshift’s initial research shows MCRB’s SER-109 garnering much support from Wall Street and the FDA,which should hasten its time to market. Given SER-109’s exceptional 97% cure rate for the infectious CDI, MCRB hopes […]

Read more...

Exact Sciences’ Cologuard the Preferred Test for Patients Refusing Colonoscopy (EXAS)

Research Question: Will Exact Sciences’ Cologuard become physician’s screening test of choice for colon cancer? Companies: ABT, BDX, BIOC, BSX, CHEK, CPHD, DGX, EXAS, FMI, GIVN, GSK, IRWD, RHHBY By: David Franklin Click here to download the report (.pdf)   Summary of Findings Exact Sciences Corp.’s (EXAS) Cologuard has high clinical value, but it is unlikely […]

Read more...

Exact Sciences Whisper

Exact Sciences Whisper

Research Question: Will Exact Sciences’ Cologuard become the colon cancer screening test of choice for physicians? Report Available: August 14, 2015   Blueshift’s initial research shows EXAS’s Cologuard, a non-invasive test for colon cancer, is monetizing at a significant rate following FDA approval and an increased sales staff. But some physicians argue the screener should not be […]

Read more...